Dantrolene
- Generic Name
- Dantrolene
- Brand Names
- Dantrium, Revonto, Ryanodex, Agilus
- Drug Type
- Small Molecule
- Chemical Formula
- C14H10N4O5
- CAS Number
- 7261-97-4
- Unique Ingredient Identifier
- F64QU97QCR
- Background
Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
- Indication
For use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
- Associated Conditions
- Malignant Hyperthermia, Spasticity
The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT03762109
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
- Conditions
- Exertional Heat Stroke
- Interventions
- Other: Standard of Care
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03600376
- Locations
- 🇸🇦
Mina al Jisr Hospital, Mina, Saudi Arabia
🇸🇦King Faisal Hospital, Mecca, Saudi Arabia
🇸🇦Mina Al-Wadi Hospital, Mina, Saudi Arabia
Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)
- Conditions
- Drug Toxicity Psychotropic Agents Psychostimulants
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03189433
- Locations
- 🇺🇸
CrowdRx Medical Office- Moonrise Festival, Baltimore, Maryland, United States
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2025-04-27
- Target Recruit Count
- 250
- Registration Number
- NCT03109288
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
- Conditions
- Wolfram SyndromeAtaxiaDiabetes MellitusOptic Nerve Atrophy
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT02829268
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02513095
Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
- Conditions
- Healthy Volunteers
- Interventions
- Behavioral: PhentermineDrug: Placebo Cohort 1Drug: Placebo Cohort 2
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2024-10-16
- Target Recruit Count
- 47
- Registration Number
- NCT01950520
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety Study of Dantrolene in Subarachnoid Hemorrhage
- Conditions
- Cerebral VasospasmSubarachnoid Hemorrhage
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 31
- Registration Number
- NCT01024972
- Locations
- 🇺🇸
UMASS Medical School / UMass Memorial Medical Center, Worcester, Massachusetts, United States
Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage
- Conditions
- Cerebral Vasospasm After Subarachnoid Hemorrhage
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2012-05-25
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 10
- Registration Number
- NCT00964548
- Locations
- 🇺🇸
UMASS Memorial Medical Center/UMASS Medical School, Worcester, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 34
- Registration Number
- NCT00796900
- Locations
- 🇦🇹
Medical University Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.